Phase 2
Bluebird has been chosen to receive the Cooley Anemia Foundation’s Humanitarian of the Year Award at its annual gala in June.
Just about every week has plenty of exciting news in the biopharmaceutical industry, and this week was no different. Here’s a brief look back at some of our top stories.
Ironwood Pharmaceuticals will split into two independent companies, Ironwood and what is currently being dubbed R&D Co.
Overall, Pfizer posted a good first quarter, with sales slightly higher and a 14 percent increase in profits due to lower restructuring costs and a significantly lower tax rate. However, revenue was below Wall Street expectations.
Acceleron Pharma Inc. announced its experimental facioscapulohumeral muscular dystrophy (FSHD) treatment ACE-083 garnered the Fast Track designation from the U.S. Food and Drug Administration.
Allergan Chief Executive Officer Brent Saunders delivered a rosy review of the first quarter for 2018, including a 3 percent growth in revenue to $3.67 billion over the past three months. However, investors are not terribly pleased and shares have fallen nearly 4 percent this morning.
Regeneron and its longtime development partner Sanofi are keeping their proverbial fingers crossed that their profitable collaboration will yield yet another approved treatment this year.
Mereo pulled its planned initial public offering (IPO) on the Nasdaq Global Market, saying market conditions were not in the best interests of its shareholders. The company’s statement is getting some pushback from investors and analysts.
Shares of Denmark-based Saniona are up more than 14 percent on the Stockholm Exchange after the company announced it has been cleared to initiate the second part of a mid-stage trial to develop a treatment for adolescents with Prader-Willi Syndrome.
At the World Medical Innovation Forum, panelists observed that AI can be used to scour old clinical trial data for new applications and possibly take over part of clinical trials in “virtual” models.
PRESS RELEASES